نتایج جستجو برای: hormone refractory prostate cancer

تعداد نتایج: 1104273  

Journal: :Science 2012
Kexin Xu Zhenhua Jeremy Wu Anna C Groner Housheng Hansen He Changmeng Cai Rosina T Lis Xiaoqiu Wu Edward C Stack Massimo Loda Tao Liu Han Xu Laura Cato James E Thornton Richard I Gregory Colm Morrissey Robert L Vessella Rodolfo Montironi Cristina Magi-Galluzzi Philip W Kantoff Steven P Balk X Shirley Liu Myles Brown

Epigenetic regulators represent a promising new class of therapeutic targets for cancer. Enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2), silences gene expression via its histone methyltransferase activity. We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor....

2010
David P. Turner

Most advanced prostate tumors are dependent upon hormonal regulation of the transcriptional activity of the androgen receptor (AR). Current ASCO recommendations for initial treatment of advanced disease target the hormonal mediated regulation of AR activation through androgen deprivation therapy. Despite early treatment efficacy, most prostate tumors progress and re-activate AR transcriptional ...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2008
C N Sternberg

Prostate cancer represents a major health problem. It is the second most common cancer in men worldwide, with an estimated 2.6 million new cases each year in Europe. Prostate-specific antigen (PSA) testing has radically changed practice, as most patients are now diagnosed at an earlier stage when potentially curative treatment is possible. Nonetheless, prostate cancer continues to be the second...

Journal: :Cancer research 2002
Spyro Mousses Lukas Bubendorf Urs Wagner Galen Hostetter Juha Kononen Robert Cornelison Natalie Goldberger Abdel G Elkahloun Niels Willi Pasi Koivisto William Ferhle Mark Raffeld Guito Sauter Olli-P Kallioniemi

To explore molecular mechanisms of prostate cancer progression, we applied tissue microarrays (TMAs) to analyze expression of candidate gene targets discovered by cDNA microarray analysis of the CWR22 xenograft model system. A TMA with 544 clinical specimens from different stages of disease progression was probed by mRNA in situ hybridization and protein immunohistochemistry. There was an excel...

Journal: :Surgical oncology 2005
S R J Bott M Arya I S Shergill M Williamson

Prostate cancer is one of the most commonly diagnosed and potentially devastating cancers in men, throughout the world. However, the clinical manifestation of this disease varies greatly, from indolent tumours, requiring little or no treatment, to those aggressive cancers which require radical therapies. Prostate cancer, like all other cancers, develops and progresses as a consequence of an acc...

2009
Adaikkalam Vellaichamy Arun Sreekumar John R. Strahler Theckelnaycke Rajendiran Jindan Yu Sooryanarayana Varambally Yong Li Gilbert S. Omenn Arul M. Chinnaiyan Alexey I. Nesvizhskii

Prostate cancer remains the most common malignancy among men in United States, and there is no remedy currently available for the advanced stage hormone-refractory cancer. This is partly due to the incomplete understanding of androgen-regulated proteins and their encoded functions. Whole-cell proteomes of androgen-starved and androgen-treated LNCaP cells were analyzed by semi-quantitative MudPI...

Journal: :Pain physician 2001
C W Slipman R K Patel E S Siegelman M Cirigliano A L Bhat Z Isaac D Lenrow

Prostate cancer is the most commonly diagnosed cancer and the second most common cause of cancer death among American men. To our knowledge, the highest reported prostate specific antigen (PSA) level on initial presentation is 3280 ng/mL. In this case report, we discuss a 46-year-old African-American man with back pain of 1-month's duration. A magnetic resonance imaging study of the lumbar spin...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2007
Nicholas G Nickols Peter B Dervan

Androgen receptor (AR) is essential for the growth and progression of prostate cancer in both hormone-sensitive and hormone-refractory disease. A DNA-binding polyamide that targets the consensus androgen response element binds the prostate-specific antigen (PSA) promoter androgen response element, inhibits androgen-induced expression of PSA and several other AR-regulated genes in cultured prost...

2012
Xing Hua Lina Yu Wenhai Pan Xiaoxiao Huang Zexiao Liao Qi Xian Li Fang Hong Shen

BACKGROUND To investigate the expression of Golgi phosphoprotein-3 (GOLPH3) in prostate cancer and determine its prognostic value. METHODS Immunohistochemical staining for GOLPH3 was performed on tissue microarrays of 342 prostate patients. The correlation between GOLPH3 expression with its clinicopathologic factors was also analyzed in order to determine its prognostic significance. RESULT...

2000
Hideaki Miyake Kim N. Chi Martin E. Gleave

Although numerous chemotherapeutic regimens have been evaluated for patients with hormone-refractory prostate cancer, none has improved survival. Testosteronerepressed prostate message-2 (TRPM-2), which is highly up-regulated after androgen withdrawal and during androgen-independent progression in prostate cancer, has been shown to inhibit apoptosis induced by various kinds of stimuli. The obje...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید